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Abstract 
Stem cell released molecules (SRM) production employs a proprietary manufacturing process that allows the collection of a 
wide variety of soluble and properly folded proteins and signaling molecules with complete post-translational modifications and 
exosome packaging from multiple stem cell types important to immune modulation, and tissue repair and regeneration. The 
advantages of the process are in the production of biologically active proteins, exosomes, and signaling molecules, developing a 
“systems therapeutic” yielding a combination of many molecules, that act at multiple targets, resulting in a synergistic 
therapeutic with emergent therapeutic value. Furthermore, the production of the SRM (stem cell released molecules) does not 
require downstream solubilization, refolding, or other processes. Additionally, the process offers reduced purification 
requirements and lower production costs than other pharmacological and biological processes. The production of a “systems 
therapeutic” with a multitude of molecules represents a multi-targeted, systems biology approach to designing and 
manufacturing therapeutics, including therapeutics designed to work alone, or augment scaffolding-based and/or cell-based 
regenerative medicine. 
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1. Introduction 
Stem cell released molecules (SRM) represent a “systems therapeutic” where a multitude of molecules released 
from stem cells, including adult stem cells, act through a variety of mechanisms to induce repair and regeneration 
of tissue [1]. Indeed, the SRM developed as a “systems therapeutic” is bio-inspired and mimics the endogenous 
stem cell healing in the human body [2]. Because up to 80% of the therapeutic value of adult stem cells in the 
human body is through the release of SRM, as opposed to differentiation of the stem cell into mature tissue [3], 
SRM technology is valuable when used alone as a therapeutic, or when used in conjunction with cell-based and/or 
scaffolding-based therapeutics. 
2. S2RM 
Demonstrated in recent years has been that two or more stem cell types home into the damaged tissue where 
each cell type releases a particular pool of SRM into the target site to induce healing. Because each stem cell type 
releases a unique, but often, overlapping pool of SRM, the two or more pools of SRM acting in a synergistic 
manner has been described as S2RM [1]. The S2RM technology represents a new direction in the development of 
therapeutics, distinct from traditional reductionist methods where one small molecule is developed to interact with 
one primary target pathway [4]. Indeed, reverse engineering led to the S2RM technology where natural stem cell 
healing processes are mimicked such that a multitude of target pathways underlying the particular indication can be 
identified and perturbed for amelioration by the molecules. 
 
 
Figure 1. S2RM is the stem cell released molecules from two or more types of stem cells. SRM from pool 1 combines with SRM from pool 2 to 
form a synergistic combination pool of SRM termed S2RM. The pool of S2RM contains a fraction of exosomes. 
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3. Exosomes 
Exosomes from stem cells are naturally occurring nanospheres composed of a lipid bilayer, much like a 
liposome. Important to the exosome is their ability to very efficiently protect, transport, and deliver their contents, 
which is a wide variety of molecules (SRM), to surrounding cells. The exosome is naturally produced by adult 
stem cells in culture if the stem cells are properly processed through to final secretion of the SRM that contains the 
exosomes. That is, collecting the secretome, instead of the lysate, is critical to proper production of SRM and 
exosomes. Exosomes are especially important for the development of biologics and drug delivery for the 
aforementioned reasons, and also because the exosomes from stem cells is immunologically inert [5], and can pass 
through the blood-brain barrier [6]. This will be more thoroughly described in a later section.  
4. Stem cell S2RM processing  
The processing of stem cells for the production of S2RM and exosomes requires a number of important steps. 
First, the stem cell types relevant to the particular tissue and to the indication are identified. Second, each cell type 
must be cultured and stimulated in a manner to best elicit the SRM. 
 
 
 
Figure 2A (Above). Stem cells derived from ileum. 2B (Below). Exosomes secreted from an adult stem cell are shown in dark-field microscopy 
as the vast number of white dots in the upper regions of the micrograph... 
Third, the stem cells must be allowed to fully process their molecules to the point of secretion into the 
extracellular space, and fourth, the molecules and exosomes must be collected. 
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4.1. S2RM versus other processing technologies 
The S2RM processing technology for the development of therapeutics is significantly different from other 
technologies in a number of ways. As we can contrast in Figure 3, S2RM secretome processing has a number of 
advantages over other technologies. First, S2RM possesses all of the molecules that are relevant and needed for 
tissue repair and regeneration, whereas other technologies only contain a fraction of the needed molecules. Second, 
because the secretome is utilized instead of a lysate, the molecules of the SRM have been allowed to complete their 
post-translational modifications (PTM), whereas other technologies will use molecules that have not completed 
PTM and are therefore dysfunctional because of mis-folding and improper moiety formation. Third, the secretome 
processing allows for the complete molecular packaging of the molecules into exosomes for protection, transport, 
and delivery to neighboring cells. Incomplete molecular packaging can leave the molecules unprotected, poorly 
transportable, and without efficient delivery to neighboring cells. And, fourth, because native stem cells instead of 
quasi-stem cells such as iPSCs and parthenogenetic stem cells are used in S2RM, no genetic or epi-genetic 
programming errors are introduced into the cell’s mechanisms for producing the S2RM. In contradistinction to 
adult stem cells used in S2RM processing, the quasi-stem cells suffer from many genetic and epi-genetic 
programming errors rendering a cell type that is severely dysfunctional and producing an incomplete set of 
molecules [7,8,9,10].  
 
 
Figure 3. S2RM secretome processing offers a number of advantages for producing therapeutics compared to other techniques. 
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4.2. Exosome processing 
Exosomes from stem cells have been concentrated and separated using a proprietary, patent-pending technology 
developed at BioRegenerative Sciences, Inc. When fully developed and processed for concentration and collection, 
the exosomes will be replete with many signaling molecules including growth factors, microRNA, and 
proteasomes for protein debris removal [11].  
4.2.1. Exosomes from ileum immune system 
Developing an immune system-derived exosome preparation, our experimental results show that in all analyses 
of ileum, the production of lineage negative, sca-1-positive, and cKIT positive cells far exceeds the best results 
obtained from bone marrow. Empirical findings suggest that the natural matrix of the ileum is inhibitory to the 
augmentation of these putative stem cells in semi-solid media, and that further mincing of the matrix-stripped 
explants yields unprecedented quantities of lineage-/sca-1+/cKIT+ cells. The patent uses a process whereby buffers 
dissolve the matrix that encase the exosomes, and the exosomes are then easily collected. Taking care to hydrate 
the culture chambers can provide months of continuous, sterile, expansion of cells targeted by our strategy-the cells 
that continue to proliferate the most In Vitro, and by definition, have the most uncommitted lineage-generating 
potential. Survival of the cultured ileum derived stem cells under defined culture conditions results in a distinct, 
spatially and temporally patterned release of exosomes from the ileum derived stem cells (IDSCs). When the 
release of the exosomes is into a specially constructed thickened, semi-solid media that surrounds the stem cells, 
the physical isolation of the exosomes is achieved by simple extraction methods of that portion of the media 
containing the exosomes. 
5. Developing the artificial stem cell niche 
Adult stem cells exists throughout most of the adult body, and exists within a very complex, specialized 
compartment called the stem cell niche [12]. Systemic or bolus injections of S2RM into tissue alone in some ways 
mimic the niche in providing homing, survival, and proliferation signaling [1,12]. To build or repair missing or 
highly damaged tissue, scaffolding and/or stem cells may be needed in addition to the S2RM. The scaffolding can 
provide many signalling substrates not otherwise present. For example, mechanical signal transduction can be so 
profound that mechanical forces exerted through the cell’s plasma membrane directly to the nucleus can change 
DNA expression [13,14], and rapidly change stem cell function [15]. As such, the physical and biochemical 
parameters of the scaffold can be regulated under static and/or dynamic control. 
For example, a force f will strain any physically linked protein and affect the kinetic rate k of a protein-protein 
interaction or conformation change as: 
 
k~koexp(f/fo)  (1) 
 
Indeed, stem cells normally depend on an elastic matrix for many functions [16], and may possess more than the 
typical ensemble of force-coupled signalling pathways as a means to sensitize themselves to microenvironments 
that range in the physical dimension from flowing fluids and strained tissues to solid tissues of varied elasticity 
[17], and the numerous physical changes in tissues associated with disease and trauma. 
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Figure 4. Scaffolding composed of biopolymer and S2RM produces a matrix with stem cell attractant, and other signaling properties thus 
producing a quasi-natural tissue construct to build and repair damaged tissues and organs. 
Recent advances in dynamic scaffold design include incorporating various polymers into porous foams that shift 
in stiffness, and controlling the surface topology of the pores and thus the distribution and size of the places where 
cells and proteins attach in three dimensional space [18]. This technique could allow bioengineers to create self-
assembling scaffolds that control, for example, where signaling molecules and stem cells adhere, and under what 
tensional and/or biochemical conditions the adherence will be self-implemented. 
Matrix substrates and alignments [19] and biochemical composition [20] will also play key roles for the 
instruction of stem cell function and tissue formation. For example, electrospun nanofibers of particular physical 
properties and alignments can preferentially differentiate neural stem cells into Schwann cells [19], and the 
addition of SRM into the niche or artificial niche will induce the migration of multiple somatic cell types [1,20].  
While the importance of understanding the components of the multifactorial stem cell niche is critical to 
determining stem cell fate [21], equally important is determining the multifactorial nature of controlling the stem 
cell released molecules [1]. This is important because of the huge therapeutic benefit, up to 80%, of the SRM 
compared to stem cell fate (differentiation) in adult stem cells responsible for maintenance and repair of our 
bodies. 
As shown in Fig. 4, a smart scaffold can be combined with embedded S2RM to attract native stem cells to the 
scaffold, with the S2RM to help maintain and embed the stem cells in the matrix. The S2RM also provides 
signalling, including migration and mitotic signalling, to neighbouring cells to enhance the formation of the 
artificial niche. Of course the scaffold can also be preloaded with stem cells, and the S2RM, to make the artificial 
tissue or niche. 
Interestingly, non-scaffolding means of controlling physical parameters of cells, matrix interactions, and 
juxtaposition signalling can be developed through engineered microsphere technologies [22]. In such a manner, 
SRM and differentiation parameters can be controlled in circulating or injected stem cells without the need to limit 
the cells to an interaction with a more physically constrained scaffold. 
6. Therapeutic benefits: past, present, and future 
While the private practice of stem cell-based medicine has sometimes put the “medical cart in front of the 
scientific horse,” mainstream medical stem cell therapy has been practiced for decades in the form of bone marrow 
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tissue transplants. In 1957, stem cell therapeutics made a major stake in medicine with the advent of intravenous 
infusion of bone marrow in cancer patients [23]. Now using purified stem cells rather than whole bone marrow 
taken from the patient before chemotherapy, physicians avoid re-injecting patients with their own cancer cells. 
 Today, especially in academic medical centers throughout the world, we witness an array of new therapeutic 
procedures involving stem cells. For example promising results for Type 1 diabetes has been reported [24]. Stem 
cells have also been used clinically for bone tissue repair in osteogenesis imperfecta [25], for promotion of tissue 
regeneration in myocardial infarction, and as immune modulators in the treatment of graft-versus host disease 
(GvHD) [26,27]. Organ transplant patients are now benefiting from stem cell transplantation as the stem cells reset 
the immune system and prevent organ rejection by replacing the deadly immunosuppressive drugs normally given 
to organ transplant patients [28]. 
SRM technologies as therapeutics have been on the market for years. For example, SRM from a type of 
progenitor cell has been used in an artificial skin matrix to help close diabetic foot ulcers [29], and S2RM has been 
used to treat a number of conditions, where the cells necessary for the best therapeutic effect must be carefully 
considered [1,30]. Like the promise of gene-splicing in the 1970s, which first delivered human insulin as a 
commercially viable product in 1976 and started the biotechnology industry [31], the power of stem cell 
technology is so great that an equivalent impact will be felt in society in the next decade. 
6.1. Example: Treating immune related conditions 
Let’s consider an example. Mesenchymal stem cells (MSCs) are immunosuppressive and have been used to 
treat rejection of organ transplants [28].  Numerous characteristics contribute to the effect. Besides being 
characterized by low expression of Major Histocompatibility Complex class II (MHCII) and co-stimulatory 
molecules (B7-1 and B7-2), MSCs interfere with various pathways of the immune response by means of cell-to-
cell interactions and SRM, including members of the transforming growth factor-  family, interleukins 6 and 10, 
proteasomes, matrix metalloproteinases (MMPs), nitric oxide and indoleamine 2,3 deoxygenase (IDO). Different 
studies have reported the ability of MSCs to suppress T-cell proliferation, most likely via Prostaglandin E2 (PGE2) 
production [32], to induce T regulatory cells [33], and to express co-inhibitory molecules as B7-H1 on their surface 
upon IFN-  treatment [34]. Further, MSCs can impair maturation and function of dendritic cells and inhibit the 
proliferation, differentiation, and chemotaxis of B-cells in vitro [35]. 
The immune-stimulating properties of these adult stem cells have been reported in some studies and may 
depend on the production of pro-inflammatory cytokines [36]. Evidence suggests that dual immunoregulatory 
function of MSCs is dose-dependent, because high numbers of MSCs suppress whereas very low numbers seem to 
stimulate lymphocyte proliferation [37]. Dose dependency has important implications in the use of MSCs as cell-
therapeutics, as the dosing schedule is likely critical for the in vivo function and may rely on factors that are not 
well-understood, thereby limiting widespread use in the clinic. Such problems for stem cells may be mitigated by 
using the S2RM instead of the cells where possible immune stimulation is eliminated or mitigated, and where 
dosing of the molecules can be under much better control in space and time. Here too, the smart scaffolding may 
play a role in releasing the S2RM/exosomes from the scaffolds defined physical dimension, while also potentially 
releasing the molecules on a demand basis, for example, when the scaffold senses hypoxic conditions or a physical 
change such as swelling. 
6.2. Stem cell therapeutics without cells 
Of great importance to the advancement of stem cell-based therapeutics are the observations that exosomes are 
immunoprivileged [5] and that ongoing MSC-based trials for treatment of disease, including cardiovascular 
diseases as an example, reveal an interesting trend in clinical trial designs, in that SRM mechanisms for improving 
angiogenesis, cardio-myogenesis, stimulating endogenous cardiac progenitors and inhibiting remodelling have 
been highlighted as the primary mode of action [38]. Inflammation underlies a number of diseases and other 
indications, and recent studies show that many conditions involving inflammation can be successfully treated with 
stem cells, including asthma [39], where S2RM has been shown to be helpful (author’s observation). More and 
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more studies report that the therapeutic effect of stem cells can be largely attributed to their SRM [3,40]. Thus, the 
current research portends an advantage to systems biology-based S2RM and exosome methodologies when used 
alone, or in conjunction with cell technologies and/or scaffolding technologies for the development of therapeutics 
to address many indications. 
Considering the blind men and the elephant parable from ancient India, if we choose to consider disease and 
other indications in a reductionist manner as involving one leg, or one tail, and then developing a therapeutic to 
treat that one pathway, the leg, or the tail, we will fail to recognize the elephant and therefore neither recognize the 
condition nor provide the best treatment. Reverse engineering natural stem cell repair and regeneration 
mechanisms, where the stem cells have evolved to recognize the many pathways of the elephant, and thus the 
elephant becomes an emergent property of the system, leads to better therapeutics through the development of stem 
cell-based bioinspired “systems therapeutics.” 
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